ClinicalTrials.gg
CompletedNCT04680767Updated May 26, 2026Results posted

A Study of LY3502970 in Healthy Male Participants

A Phase 1 interventional study of [¹⁴C]-LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
35 Years to 55 Years
Sex
Male
01

Study summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to 8 weeks (maximum).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males
  • Body weight within 50 and 100 kilograms (kg), inclusive, and within the range 18.0 and 32.0 kilograms per square meter (kg/m²) (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Females
  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the product (IP); or of interfering with the interpretation of data
  • Have a history of Gilbert's syndrome or have total level (TBL) above (ULN) at screening
  • Have evidence of significant active neuropsychiatric disease, as determined by the investigator
  • Have had any exposure to LY3502970 or any other glucagon-like peptide-1 (GLP-1) analogs, or other related compounds within the prior 3 months, or any history of allergies to these medications
  • Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated, within the last 3 months, in a clinical study involving an IP. If the previous IP has a long half-life, 5 half-lives or 3 months (whichever is longer) should have passed, prior to check-in
  • Have participated in any clinical trial involving a radiolabeled IP within 12 months prior to check-in
  • Show evidence of (HIV) infection and/or positive HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
  • Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing (e.g., serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    3mg [¹⁴C]-LY3502970

    Participants received a single oral dose of 3 milligrams (mg) of carbon-14-labeled \[¹⁴C\]-LY3502970, containing approximately 200 microcuries (µCi) of radioactivity on Day 1.

    Drug: [¹⁴C]-LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Feces excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Feces samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.

    Time frame: 0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose

  2. Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Urinary excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Urine samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.

    Time frame: 0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970

    PK: AUC0-tlast of plasma LY3502970

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

  2. PK: Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration ((AUC0- Tlast) of Total Radioactivity in Plasma and Whole Blood

    PK: AUC0-tlast of total radioactivity in plasma and whole blood

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

  3. PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970

    PK: AUC(0-∞) of plasma LY3502970

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

  4. PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Total Radioactivity in Plasma and Whole Blood

    PK: AUC(0-∞) of total radioactivity in plasma and whole blood

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

  5. PK: Maximum Concentration (Cmax) of Plasma LY3502970

    PK: Cmax of plasma LY3502970

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

  6. PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood

    PK: Cmax of total radioactivity in plasma and whole blood

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

  7. Total Number of Metabolites of LY3502970 in Plasma, Urine and Feces

    * Total number of metabolites of LY3502970 in plasma, urine and feces samples pooled across participants to assess the presence of metabolites. * Urine and feces samples collected as a 12-hour predose interval (-12 to 0 hour \[h\], where 0h = time of dose administration) and then continuously postdose in specified intervals through 384h were used to assess this outcome. * Feces Sample collection time frame : -12 to 0, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose

    Time frame: Plasma: 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 h postdose; Urine: -12 to 0, 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose

07

Results

Posted May 26, 2026

Participant flow

Participant flow — Overall Study
Milestone3mg [¹⁴C]-LY3502970
Started6
Received at least one dose of study drug6
Completed6
Not completed0

Outcome measures

PrimaryFeces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Feces excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Feces samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.

Time frame:
0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose
Reported as:
Mean · percentage of the total radioactive dose
Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
percentage of the total radioactive dose3mg [¹⁴C]-LY3502970
Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered86.75 ± 2.78
PrimaryUrinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Urinary excretion of LY3502970 radioactivity over time expressed as a percentage of the total radioactive dose administered. Urine samples collected from 0 hour (h), where 0h = time of dose administration, through 384h postdose were used to assess this outcome.

Time frame:
0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose
Reported as:
Mean · percentage of the total radioactive dose
Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
percentage of the total radioactive dose3mg [¹⁴C]-LY3502970
Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered0.24 ± 0.02
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970

PK: AUC0-tlast of plasma LY3502970

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Reported as:
Geometric mean · nanogram*hour per milliliter(ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970
nanogram*hour per milliliter(ng*h/mL)3mg [¹⁴C]-LY3502970
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970210 ± 14
SecondaryPK: Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration ((AUC0- Tlast) of Total Radioactivity in Plasma and Whole Blood

PK: AUC0-tlast of total radioactivity in plasma and whole blood

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Reported as:
Geometric mean · nanogram equivalents*hour per milliliter
PK: Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration ((AUC0- Tlast) of Total Radioactivity in Plasma and Whole Blood
nanogram equivalents*hour per milliliter3mg [¹⁴C]-LY3502970
AUC0-tlast of Plasma Total Radioactivity266 ± 21
AUC0-tlast of Whole Blood Total Radioactivity103 ± 19
SecondaryPK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970

PK: AUC(0-∞) of plasma LY3502970

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Reported as:
Geometric mean · nanogram*hour per milliliter(ng*h/mL)
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970
nanogram*hour per milliliter(ng*h/mL)3mg [¹⁴C]-LY3502970
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970223 ± 13
SecondaryPK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Total Radioactivity in Plasma and Whole Blood

PK: AUC(0-∞) of total radioactivity in plasma and whole blood

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Reported as:
Geometric mean · nanogram equivalents*hour per milliliter
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Total Radioactivity in Plasma and Whole Blood
nanogram equivalents*hour per milliliter3mg [¹⁴C]-LY3502970
AUC(0-∞) of Plasma Total Radioactivity292 ± 21
AUC(0-∞) of Whole Blood Total Radioactivity135 ± 17
SecondaryPK: Maximum Concentration (Cmax) of Plasma LY3502970

PK: Cmax of plasma LY3502970

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Reported as:
Geometric mean · nanogram per milliliter(ng/mL)
PK: Maximum Concentration (Cmax) of Plasma LY3502970
nanogram per milliliter(ng/mL)3mg [¹⁴C]-LY3502970
PK: Maximum Concentration (Cmax) of Plasma LY350297010.4 ± 14
SecondaryPK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood

PK: Cmax of total radioactivity in plasma and whole blood

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose
Reported as:
Geometric mean · nanogram equivalents per milliliter
PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood
nanogram equivalents per milliliter3mg [¹⁴C]-LY3502970
Cmax of Plasma Total Radioactivity10.7 ± 17
Cmax of Whole Blood Total Radioactivity5.92 ± 16
SecondaryTotal Number of Metabolites of LY3502970 in Plasma, Urine and Feces

* Total number of metabolites of LY3502970 in plasma, urine and feces samples pooled across participants to assess the presence of metabolites. * Urine and feces samples collected as a 12-hour predose interval (-12 to 0 hour \[h\], where 0h = time of dose administration) and then continuously postdose in specified intervals through 384h were used to assess this outcome. * Feces Sample collection time frame : -12 to 0, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose

Time frame:
Plasma: 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 h postdose; Urine: -12 to 0, 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose
Reported as:
Number · number of metabolites
Total Number of Metabolites of LY3502970 in Plasma, Urine and Feces
number of metabolites3mg [¹⁴C]-LY3502970
Plasma2
UrineNA
Feces12

Adverse events

Collected over Baseline up to Day 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3mg [¹⁴C]-LY35029700/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 12
Most frequent other events
Event3mg [¹⁴C]-LY3502970
NauseaGastrointestinal disorders5/6
Abdominal distensionGastrointestinal disorders2/6
DiarrhoeaGastrointestinal disorders2/6
VomitingGastrointestinal disorders2/6
Decreased appetiteMetabolism and nutrition disorders2/6
Abdominal painGastrointestinal disorders1/6
Vessel puncture site bruiseGeneral disorders1/6
DizzinessNervous system disorders1/6
Head discomfortNervous system disorders1/6
HeadacheNervous system disorders1/6

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)3mg [¹⁴C]-LY3502970
Mean42.8 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)3mg [¹⁴C]-LY3502970
Female0
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)3mg [¹⁴C]-LY3502970
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)3mg [¹⁴C]-LY3502970
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)3mg [¹⁴C]-LY3502970
United Kingdom6
08

Study locations

1 site
  • Covance Clinical Research
    Leeds, LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jul 2021, 3 months.

Results were first posted in May 2026, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 23, 2020
StartActual
Mar 29, 2021
Primary completionActual
Jul 3, 2021
CompletionActual
Jul 3, 2021
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04680767
Responsible party
Sponsor
First posted
Dec 23, 2020
Start date
Mar 29, 2021
Primary completion
Jul 3, 2021
Completion
Jul 3, 2021
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion